Scinai Publishes Q1 2024 Financial Results and Provides Business Update

Rhea-AI Summary

Scinai Immunotherapeutics (Nasdaq: SCNI) announced its Q1 2024 financial results, revealing key developments and financial metrics. The company raised $1.69 million via warrants issuance in January and regained compliance with Nasdaq’s $1.00 bid price requirement in June but remains non-compliant with the equity requirement.

The CDMO unit received $500K in work orders in the first half of 2024, with projected 2024 revenues of $1.25 million. Pipeline developments include promising preclinical results for NanoAb treatments for plaque psoriasis and collaborations for COVID-19 and anti-IL-17 treatments.

Financially, Scinai reported a net loss of $2.159 million, down from $3.515 million in Q1 2023. R&D expenses decreased to $1.568 million, and marketing, general, and administrative expenses fell to $484K. As of March 31, 2024, the company held $4.826 million in cash and equivalents.

Positive

• Raised $1.69 million via warrants issuance in January.
• CDMO unit received $500K in work orders in the first half of 2024.
• Projected CDMO revenues of $1.25 million for 2024.
• Net loss decreased to $2.159 million from $3.515 million in Q1 2023.
• R&D expenses decreased to $1.568 million from $1.995 million in Q1 2023.
• Marketing, general, and administrative expenses decreased to $484K from $1.191 million in Q1 2023.

Negative

• Company remains non-compliant with Nasdaq's equity requirement.
• Cash and equivalents slightly decreased to $4.826 million from $4.870 million as of March 31, 2023.

Insights

Financial Analyst

Scinai Immunotherapeutics' Q1 2024 financial results reveal several key elements investors should consider. First, the company reported a net loss of $2.16 million, a notable improvement from the previous year’s same period net loss of $3.52 million. This reduction is primarily due to decreased R&D and administrative expenses, reflecting the company’s efforts to streamline operations amid financial restructuring. Despite this, the company's current cash position of $4.83 million remains comparable to the previous year’s $4.87 million, suggesting effective cash management amidst ongoing financial challenges.

Scinai's debt conversion plan with EIB could be pivotal. Converting a significant portion of the debt into equity could improve the balance sheet and potentially help regain compliance with Nasdaq’s equity requirements. This move, however, dilutes existing shareholders, which may impact stock value in the short term.

Investors should also note the company’s ongoing efforts to build its CDMO business, projecting $1.25 million in revenues for 2024. While these projections are promising, the CDMO unit needs to meet high operational standards and client acquisition targets to realize these revenue figures. Overall, while the company appears to be stabilizing, the long-term sustainability will hinge on successful debt restructuring and CDMO growth.

Market Research Analyst

Scinai’s strategic pivot towards developing its CDMO services is a move worth monitoring. The company's advanced contract discussions and the work orders valued at $500K in the first half of 2024 underscore its focus on capturing market share in a rapidly growing sector. The global CDMO market is expanding, driven by increasing demand from biotech firms for outsourced manufacturing services. By targeting early-stage biotech companies, Scinai positions itself in a niche segment with potentially high growth opportunities.

However, the company’s ability to build credibility and meet stringent quality standards will be critical. The emphasis on rapidly scalable, high-quality services at competitive prices is apt, but execution risks remain high in this competitive landscape. The recent marketing activities and educational courses indicate proactive efforts to build brand awareness and industry connections, which are important for long-term success.

For retail investors, the CDMO segment could represent a significant revenue stream, but it is still in its nascent stage. It will be essential to monitor how quickly and effectively Scinai can convert these efforts into substantial and sustained revenue growth.

Biopharmaceutical Expert

Scinai’s progress in their NanoAb preclinical development and in vivo proof of concept studies, especially for treating plaque psoriasis, highlights a promising direction for their R&D pipeline. The collaboration with Prof. Amos Gilhar and other research entities suggests strong scientific foundations. The planned pre-clinical toxicology studies and potential human trials in 2025 could be significant milestones.

Additionally, Scinai’s strategic partnerships, including the Max Planck and University Medical Center Göttingen collaboration, could yield valuable novel therapeutics. These early-stage developments are crucial, but they also come with inherent risks typical of biopharmaceutical advancements – including regulatory hurdles, clinical trial outcomes and market acceptance. Investors should weigh these potential breakthroughs against the typical long timelines and high costs associated with biopharmaceutical development.

JERUSALEM, July 2, 2024 /PRNewswire/ -- Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) ("Scinai", or the "Company"), a biopharmaceutical company focused on developing inflammation and immunology (I&I) biological products and on providing CDMO services through its Scinai Bioservices business unit, today published its financial results for the quarter ended March 31, 2024, and provided a business update.

Business Update & Recent Highlights

Financing

In support of the Company's strategic pivot, on January 3, 2024, we raised $1.69 million in gross proceeds from the exercise of certain of our outstanding warrants and the issuance of new warrants. H.C. Wainwright & Co. acted as exclusive placement agent in connection with the offering.

Nasdaq Compliance and Conversion of EIB Loan into Equity

On June 7, 2024 the Company announced that on June 5, 2024, it received formal notification from the Listing Qualification Department (the "Staff") of the Nasdaq Stock Market ("Nasdaq") that the Company had regained compliance with the minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Rule"). In the notification provided by the Staff on June 5, 2024, the Staff stated that the Company remains non-compliant with the equity requirement in Listing Rule 5550(b)(1), or any of the alternative requirements under Listing Rule 5550(b), and accordingly the Company presented its plan to get back into compliance with the equity requirement with the Nasdaq Hearing Panel on June 18, 2024. The Plan presented to the panel included a debt-to-equity loan restructuring deal the Company is working on with its lender, the European Investment Bank (the "EIB").

On June 13, 2024 the Company announced that it received a letter of Intent from the EIB. This LoI outlined specific indicative terms for converting the EIB's loan into equity. The Company expects to receive a binding term sheet in July and have the financial contract with EIB fully amended by the end of August.  

Based on the above plan, the Company requested from the Nasdaq Hearing Panel an extension of the deadline for regaining compliance with the equity requirement. The Company expects to receive the decision of the Hearing Panel in the coming weeks.

CDMO business unit

In the first six months of 2024 we received CDMO work orders valued at approximately $500K, and we are in advanced contract discussions with several other potential clients. We maintain confidence in our sales guidance for 2024 of $1.25 million in expected revenues. As our CDMO unit is new and we are in a rapid growth stage, acquiring new clients and building our reputation and brand awareness of our CDMO services,  we expect revenues from the CDMO business to increase materially in the coming years. This is also coupled with growing demand for boutique CDMO services from early-stage biotech companies looking for fast project onset at competitive pricing without compromising on meeting the most stringent scientific and quality standards.

In addition, in 2024 we have been pursuing extensive targeted marketing activities, including online advertisements, direct outreach campaigns and participation in major pharmaceutical conferences, such as BIO Europe Spring in Barcelona (March 2024), and  the BioMed Israel conference  in Tel Aviv, Israel (May 2024), at which we marketed our CDMO services and met  potential partners for our R&D pipeline and potential investors.  

Our CDMO unit is currently focused both on executing drug development projects for our clients and on validating our processes and facilities to be ready for cGMP inspection by the Israeli Ministry of Health.

In June, we held a first of its kind, hands on aseptic processing course at our facility in Jerusalem in collaboration with key figures in the industry including Ms. Rachel Shimonovitz,  Head of GMP inspectorate of the Israeli Ministry of Health, and ADRES Int'l Biotech, a leading Israeli regulatory and quality consulting services firm. The course attracted many senior role holders from the Israeli biotech industry who came to our facility for this two-day education and training course.  

Pipeline Development

We are aggressively advancing the NanoAb preclinical development. At the end of April 2024, we concluded an in-vivo proof of concept animal study in collaboration with Prof. Amos Gilhar, a world-renowned dermatologist of the prestigious Technion Israel Institute of Technology. The results look promising and corroborate our aspiration for the development of a novel, local biologics therapeutic for the treatment of patients suffering from plaque psoriasis.

On June 4, 2024, we met for a scientific advisory meeting with the Paul Erlich Institute (the PEI) of Germany, the scientific advice of which is considered acceptable guidance for IMPD filing with the European Medicines Agency (EMA) and is also considered the European comparable to a pre-IND meeting with the FDA in the U.S.  We expect their final minutes of the meeting in the coming couple of weeks. Upon guidance from the PEI, we expect to commence preparations for a pre-clinical toxicology study before commencing a first-in-human clinical trial of our anti-IL NanoAbs for the treatment of plaque psoriasis in 2025.   

Additional NanoAbs for treatment of additional autoimmune diseases, such as asthma, atopic dermatitis and wet AMD, have been discovered and characterized at Max Planck and University Medical Center Göttingen as part of their research collaboration agreement with Scinai. Scinai holds exclusive options for exclusive licenses at pre-agreed financial terms for each of the resulting NanoAbs.

We are pursuing a strategic partnership for both our COVID-19 self-administered inhaled NanoAb, which demonstrated highly promising in vivo results in animals as both a therapeutic and prophylactic treatment, and our anti-IL-17 nanoAb for the treatment of plaque psoriasis and other potential indications.

Q1 2024 Financial Summary

• R&D expenses for the three months ended March 31, 2024, amounted to $1,568 thousands, compared to $1,995 thousands for the three months ended March 31, 2023. The decrease was primarily due to a reduction in salaries and reduced use of subcontractors.
• Marketing, general and administrative expenses  for the three months ended March 31, 2024, amounted to $484 thousands, compared to $1,191 thousands for the three months ended March 31, 2023. The decrease was primarily due to a reduction in each of salaries, share-based compensation and professional services.
• Financial income for the three months ended March 31, 2024, amounted to $231 thousands compared to $329 thousands for the three months ended March 31, 2023.
• Net loss for the three months ended March 31, 2024, was $2,159 thousands compared to net loss of $3,515 thousands for the three months ended March 31, 2023.

As of March 31, 2024, Scinai had cash and cash equivalents and short-term deposits of $4,826 thousands compared to $4,870 thousands as of March 31, 2023.

 

 

SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as BiondVax Pharmaceuticals Ltd.)
BALANCE SHEETS
U.S. dollars in thousands (except share and per share data)
		March 31,				December 31,
		2024				2023
ASSETS		Unaudited				Audited
CURRENT ASSETS:
Cash and cash equivalents		$	4,826			$	4,870
Restricted cash			140				140
Prepaid expenses and other receivables			288				437
Total current assets			5,254				5,447
NON-CURRENT ASSETS:
Property, plant and equipment, net			10,671				10,825
Operating lease right-of-use assets			1,126				1,200
Total non-current assets			11,797				12,025
Total assets		$	17,051			$	17,472
The accompanying notes are an integral part of the financial statements.

 

 

SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as BiondVax Pharmaceuticals Ltd.)
BALANCE SHEETS
U.S. dollars in thousands (except share and per share data)
		March 31,				December 31,
		2024				2023
		Unaudited				Audited
LIABILITIES NET OF CAPITAL DEFICIENCY
CURRENT LIABILITIES:
Trade payables		$	928			$	535
Operating lease liabilities			387				396
Other payables			610				849
Total current liabilities			1,925				1,780
NON-CURRENT LIABILITIES:
Warrants liability			-				96
Loan from others			19,510				19,368
Non-current operating lease liabilities			732				797
Total non-current liabilities			20,242				20,261
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS' DEFICIT:
Ordinary shares of no par value: Authorized: 20,000,000,000 shares at March 31, 2024 and at December 31, 2023; Issued and outstanding 2,160,346,784 shares at March 31, 2024 and 1,857,169,984 shares at December 31, 2023			-				-
Additional paid-in capital			121,118				119,506
Accumulated deficit			(124,494)				(122,335)
Accumulated other comprehensive loss			(1,740)				(1,740)
Total shareholders' deficit			(5,116)				(4,569)
Total liabilities and shareholders' deficit		$	17,051			$	17,472
The accompanying notes are an integral part of the financial statements.

 

 

SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as BiondVax Pharmaceuticals Ltd.)
STATEMENTS OF OPERATIONS
U.S. dollars in thousands (except share and per share data)
		For the three months ended March 31
		2024				2023
		Unaudited				Unaudited
Research and development expenses, net		$	1,568			$	1,995
Marketing, general, and administrative expenses			484				1,191
Other income			(124)				-
Total operating expenses			1,928				3,186
Total operating loss			1,928				3,186
Total Financial Expenses net,			231				329
Net loss		$	2,159			$	3,515
Net loss per share attributable to ordinary shareholders, basic and diluted			(0.001)				(0.003)
Weighted average number of shares used in computing net loss per share attributable to ordinary shareholders, basic and diluted			2,026,147,212				1,295,256,604
The accompanying notes are an integral part of the financial statements.

 

 

SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as BiondVax Pharmaceuticals Ltd.)
STATEMENTS OF COMPREHENSIVE LOSS
U.S. dollars in thousands (except share and per share data)
		For the three months ended March 31
		2024				2023
		Unaudited				Unaudited
Net loss		$	2,159			$	3,515
Other comprehensive income:
Foreign currency translation adjustments			-				(116)
Total comprehensive loss		$	2,159			$	3,399
The accompanying notes are an integral part of the financial statements.

 

 

SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as BiondVax Pharmaceuticals Ltd.)
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
U.S. dollars in thousands (except share and per share data)
		Ordinary shares								Additional paid-in				Accumulated comprehensive				Accumulated				Total shareholders'
		Number				Amount				capital				loss				deficit				equity
Balance as of December 31, 2022			989,290,784			$	-			$	116,082			$	(2,007)			$	(115,835)			$	(1,760)
Exercise of warrants			584,015,200				-				801				-				-				801
Vested RSU's			8,108,400				-				-				-				-				-
Issuance of warrants and shares, net of issuance costs of $86			160,000,000				-				1,086				-				-				1,086
Reclassification of warrants liability to equity			-				-				398				-				-				398
Share-based compensation			-								869				-				-				869
Shares issued for services			115,755,600				-				270				-				-				270
Other comprehensive income			-				-				-				267				-				267
Net loss			-				-				-				-				(6,500)				(6,500)
Balance as of December 31, 2023			1,857,169,984			$	-			$	119,506				$(1, 740)			$	(122,335)			$	(4,569)
Issuance of shares, net of issuance costs of $275			-				-				1,421				-				-				1,421
Share-based compensation			-				-				191				-				-				191
Net loss			-				-				-				-				(2,159)				(2,159)
Balance as of March 31, 2024			1,857,169,984			$	-			$	121,118				$(1, 740)			$	(124,494)			$	(5,116)

 

 

SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as BiondVax Pharmaceuticals Ltd.)
STATEMENTS OF CHANGES IN SHAREHOLDERS' EQUITY
U.S. dollars in thousands (except share and per share data)
		Ordinary shares								Additional paid-in				Accumulated comprehensive				Accumulated				Total shareholders'
		Number				Amount				capital				loss				deficit				equity
Balance as of December 31, 2022			989,290,784			$	-			$	116,082				$(2, 007)			$	(115,835)			$	(1,760)
Exercise of warrants			324,000,000				-				97				-				-				97
Vested RSUs			332,400								-				-				-				-
Other comprehensive income			-				-								116				--				116
Share-based compensation			-				-				252				-				-				252
Net loss			-				-				-				-				(3,515)				(3,515)
Balance as of March 31, 2023			1,313,623,184			$	-			$	116,431				$(1, 891)			$	(119,350)			$	(4,810)

 

 

SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as BiondVax Pharmaceuticals Ltd.)
STATEMENTS OF CASH FLOWS
U.S. dollars in thousands
		For the three months ended March 31,
		2024				2023
Cash flows from operating activities:
Net loss		$	(2,159)			$	(3,515)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation of property, plant and equipment			156				138
Financial income (expense) related to loan from others			225				2,354
Revaluation of warrants			(96)				-
Share-based compensation			191				252
Decrease (increase) in other receivables			149				140
Changes in operating lease right-of-use assets			75				(18)
Increase in trade payables			309				629
Changes in operating lease liabilities			(74)				7
Increase (decrease) in other payables			(239)				(369)
Net cash used in operating activities			(1,463)				(3,059)
Cash flows from investing activities:
Purchase of property, plant and equipment			(2)				(6)
Net cash used in investing activities		$	(2)			$	(6)
The accompanying notes are an integral part of the financial statements.

 

 

SCINAI IMMUNOTHERAPEUTICS LTD. (Formerly known as BiondVax Pharmaceuticals Ltd.)
STATEMENTS OF CASH FLOWS
U.S. dollars in thousands (except share and per share data)
		For the three months ended March 31,
		2024				2023
Cash flows from financing activities:
Proceed from issuance of warrants and shares, net		$	1,421				-
Net cash provided by financing activities			1,421				-
Effect of exchange rate changes on cash, cash equivalents and restricted cash			-				(224)
Increase (decrease) in cash, cash equivalents and restricted cash			(44)				(3,289)
Cash, cash equivalents and restricted cash at beginning of year			5,010				14,215
Cash, cash equivalents and restricted cash at end of year		$	4,966			$	10,926
Supplementary disclosure of cash flows activities:
(1) Cash paid during the year for:
Interest		$	143			$	725
(2) Non-cash transactions:
Reclassification of warrants liability to financial income			96				-
Exercise of warrants liability into shares		$	-			$	97
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents		$	4,826			$	10,799
Restricted cash			140				127
Cash, cash equivalents and restricted cash		$	4,966			$	10,926
The accompanying notes are an integral part of the financial statements.

 

 

About Scinai Immunotherapeutics

Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects.

Company website: www.scinai.com.

Company Contacts

Investor Relations | +972 8 930 2529 | ir@scinai.com

Business Development | +972 8 930 2529 | bd@scinai.com

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such as "expect," "believe," "intend," "plan," "continue," "may," "will," "anticipate," and similar expressions are intended to identify forward-looking statements. All statements, other than statements of historical facts, are forward-looking statements. Examples of such statements include, but are not limited to, execution of a binding term sheet providing for revised terms of the Finance Contract with EIB, the accounting impact of execution of such revised terms and the ability of the Company to regain and remain compliant with the continued listing standards of Nasdaq, the potential of Scinai's NanoAb program, expected revenues of Scinai's CDMO business and timing of pre-clinical and clinical studies of the Company's anti-IL NanoAbs for the treatment of plaque psoriasis and their results. These forward-looking statements reflect management's current views with respect to certain current and future events and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd. Risks and uncertainties include, but are not limited to,  the risk that the Company will not execute a binding term sheet  with the EIB providing for revised terms of the Finance Contract with EIB and the risk that execution of such binding term sheet will not resolve the deficiency notice of Nasdaq with respect to the Company's shareholders' equity; the risk that the Company will otherwise be unable to regain compliance and remain compliant with the continued listing requirements of Nasdaq; lower than anticipated revenues of Scinai's CDMO business in 2024 and thereafter, failure to sign agreements with other potential clients of the CDMO business; a delay in the commencement and results of pre-clinical and clinical studies, the risk of delay in, Scinai's inability to conduct, or the unsuccessful results of, its research and development activities, including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business strategy may not be successful; the risk that the European Investment Bank (EIB) may accelerate the financial facility under its finance contract with Scinai; Scinai's ability to acquire rights to additional product opportunities; Scinai's ability to enter into collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai's manufacturing facility in Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications and other vaccine and treatment technologies; and the risk that drug development involves a lengthy and expensive process with uncertain outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading "Risk Factors" in the Company's Annual Report on Form 20-F filed with the Securities and Exchange Commission ("SEC") on May 15, 2024, and the Company's subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement for any reason.

Logo - https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg

View original content:https://www.prnewswire.com/news-releases/scinai-publishes-q1-2024-financial-results-and-provides-business-update-302187977.html

SOURCE Scinai Immunotherapeutics Ltd.

FAQ

What were Scinai's Q1 2024 financial results?

Scinai reported a net loss of $2.159 million, down from $3.515 million in Q1 2023. R&D expenses were $1.568 million, and marketing, general, and administrative expenses were $484K.

Did Scinai raise any funds in Q1 2024?

Yes, Scinai raised $1.69 million in gross proceeds from the exercise of warrants and issuance of new warrants in January 2024.

What is the status of Scinai's compliance with Nasdaq requirements?

Scinai regained compliance with Nasdaq’s $1.00 bid price requirement in June 2024 but remains non-compliant with the equity requirement.

How is Scinai's CDMO business unit performing?

The CDMO unit received work orders valued at $500K in the first half of 2024 and projects revenues of $1.25 million for the year.

What are Scinai's plans for their NanoAb pipeline?

Scinai is advancing preclinical development for NanoAb treatments for plaque psoriasis, with plans for a first-in-human clinical trial in 2025, and is exploring strategic partnerships for its NanoAb treatments.

How much cash and equivalents did Scinai have as of March 31, 2024?

Scinai held $4.826 million in cash and cash equivalents as of March 31, 2024.